Insilico Medicine Overview
Pro stress-test →Insilico Medicine is a clinical-stage generative artificial intelligence (AI)-driven drug discovery company that uses genomics, big data analysis, and deep learning for in silico drug discovery. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code HKEX: 03696. The company has achieved significant commercial momentum through landmark partnerships and clinical progress with its proprietary Pharma.AI platform.
Strategic Profile
Pro stress-test →Insilico continues to drive deep integration of cutting-edge AI technology with extensive scientific expertise, building a diversified internal pipeline covering over 40 innovative programs and 28 drug candidates at the IND-enabling stage, of which 12 have received IND clearance. The company operates a diversified business model spanning software licensing to leading pharma, out-licensing deals, and AI-enabled drug discovery collaborations, positioning it as a bridge between Big Pharma and AI-driven innovation in therapeutic development.
Competitive Landscape
Pro stress-test →BenevolentAI is among Insilico Medicine's competitors in the AI-driven drug discovery space. Insilico differentiates through its proprietary Pharma.AI platform spanning target validation to molecule optimization, clinical-stage proof-of-concept with rentosertib, and demonstrated ability to secure partnerships with top-20 pharma companies. The company's dual-purpose target identification (addressing both disease and aging) positions it uniquely in the emerging longevity biotech market.
Industry Context
Insilico Medicine operates in AI-driven drug discovery and development.
Key facts
Founded: 2014 · Headquarters: Boston, Massachusetts (with operations in Hong Kong and Abu Dhabi) · Employees: 317 · Revenue: $56.2M · Market cap: $2.79B